The FDA has questioned Iovance Biotherapeutics (IOVA) over promotional materials for its skin cancer treatment Amtagvi, arguing that references to overall survival data could mislead clinicians and patients about the therapy's effectiveness.

The latest FDA scrutiny arrives after a strong 90 day share price return of 28.57% and a year to date share price return of 39.29%. However, the 1 year total shareholder return of 8.00% and 3 year total shareholder return of 40.71% highlight how sentiment around future growth and risk has shifted over time.

If the regulatory headlines around Amtagvi have you reassessing biotech exposure, it may be worth widening your search across other healthcare names using our screener for 34 healthcare AI stocks

With Iovance still loss making on US$263.5 million of revenue and trading at US$3.51, the key question is whether today’s valuation reflects all the execution and regulatory risk, or if the market is already pricing in future growth.

Most Popular Narrative: 58% Undervalued

With Iovance Biotherapeutics last closing at $3.51 against a narrative fair value of $8.35, the valuation debate centers on how far Amtagvi and the broader TIL pipeline can carry future earnings.

Advancing multiple late-stage clinical programs for TIL therapies across solid tumor types (lung, endometrial, next-gen approaches) not only opens new addressable markets but also reduces reliance on Amtagvi alone, diversifying future revenue streams and stabilizing earnings outlook.

Curious what earnings trajectory and margin path justify that gap between fair value and today’s price? The narrative emphasizes compounding revenue, rising profitability, and a rich future earnings multiple.

Result: Fair Value of $8.35 (UNDERVALUED)

However, the narrative still leans heavily on Amtagvi’s commercial success and assumes smoother regulatory progress, so any pricing pressure or further approval setbacks could quickly challenge that view.

Next Steps

With sentiment clearly split between concern over risks and optimism about rewards, it makes sense to act quickly and review the details yourself, starting with the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop your research here, you risk missing other opportunities that might suit your goals better, so keep scanning the market and stay selective.

• Spot potential high flyers early by checking out 31 elite penny stocks with strong financials that already show stronger financial footing than many peers.
• Zero in on quality at a sensible price by reviewing 58 high quality undervalued stocks that pair solid fundamentals with attractive valuations.
• Prioritise resilience and capital strength by focusing on companies highlighted in our solid balance sheet and fundamentals stocks screener (39 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.